Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957593 · ClinicalTrials.gov registry record · NA
Induction of Labor With Oxytocin: When Should Oxytocin be Held?
A NA study, sponsored by Lehigh Valley Hospital.
- Completed
- Registry status
- NA
- Development phase
- 252
- Enrollment target
NCT00957593 is a NA study that has completed, run by Lehigh Valley Hospital. The registered enrollment target is 252 participants.
The verdict
NCT00957593, a NA study, has completed, sponsored by Lehigh Valley Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 252 participants
- Enrollment target
Study Summary
The investigators propose to perform a prospective randomized control trial to compare the rate of cesarean delivery in women where Oxytocin (OT) is discontinued once active labor begins (5 cm dilation) when compared with women where OT is continued at a maintenance level per the usual protocol. One study group will follow an oxytocin protocol which is incremental until 5 cm dilation and then maintained at the same level throughout labor. The second arm will follow an oxytocin protocol also incremental, but then discontinued once the cervix is 5 cm. The primary outcome will be the rate of cesarean delivery between the groups. Secondary outcomes to be evaluated will include duration of the labor, fetal heart rate abnormalities, and frequency of uterine hyperstimulation, maternal and neonatal outcomes. As mentioned in the study proposal, the proposed experimental arm is currently not performed as part of the oxytocin guidelines at the investigators' institution. One study from Israel suggests no difference in pregnancy outcomes with the proposed use of oxytocin. Although some providers stop the oxytocin in active labor for their patients, this is not a commonly performed procedure at the investigators' institution. The investigators are not aware of other institutions employing the above practice.
Interventions
- DRUG Oxytocin
- DRUG Oxytocin discontinuation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957593
The ClinicalTrials.gov registry entry for NCT00957593 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lehigh Valley Hospital, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin is the first listed.
NCT00957593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957593 about?
NCT00957593 is a clinical study titled "Induction of Labor With Oxytocin: When Should Oxytocin be Held?". The investigators propose to perform a prospective randomized control trial to compare the rate of cesarean delivery in women where Oxytocin (OT) is discontinued once active labor begins (5 cm dilation) when compared with women where OT is continued at a maintenance level per the usual protocol. On...
What is the current status of trial NCT00957593?
This trial is currently completed. It is a NA study. The enrollment target is 252 participants. The study started on 2009-02. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00957593?
The interventions under investigation include: Oxytocin (DRUG), Oxytocin discontinuation (DRUG).
Who is sponsoring clinical trial NCT00957593?
This trial is sponsored by Lehigh Valley Hospital, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.